Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Bone Disorders01:29

Bone Disorders

6.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
6.0K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

9.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A single nucleotide polymorphism in LRP2 is associated with susceptibility to Alzheimer's disease in the Chinese population.

Clinica chimica acta; international journal of clinical chemistry·2010
Same author

Three-component assembly and divergent ring-expansion cascades of functionalized 2-iminooxetanes.

Angewandte Chemie (International ed. in English)·2010
Same author

Prokaryotic expression and potential application of the truncated PCV-2 capsid protein.

Virologica Sinica·2010
Same author

Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus.

The Journal of rheumatology·2010
Same author

Peptide dendrimers as efficient and biocompatible gene delivery vectors: Synthesis and in vitro characterization.

Journal of controlled release : official journal of the Controlled Release Society·2010
Same author

The amplification and evolution of orthologous 22-kDa α-prolamin tandemly arrayed genes in coix, sorghum and maize genomes.

Plant molecular biology·2010
Same journal

Mathematical frameworks for left ventricular assist device therapy: Ventricular mechanics, blood rheology, haemodynamics, control, and nonlinear dynamics.

Progress in biophysics and molecular biology·2026
Same journal

Biological functions of BAF57, its role in disease pathogenesis, and treatment: From molecular mechanisms to clinical translation.

Progress in biophysics and molecular biology·2026
Same journal

Photonics-integrated and AI-enhanced medical sensing: From molecular diagnostics to real-time cell therapy monitoring.

Progress in biophysics and molecular biology·2026
Same journal

Uncovering the Biological Mechanisms of TREM2 with Molecular Simulations: A Comprehensive Review and Perspective.

Progress in biophysics and molecular biology·2026
Same journal

Advances in artificial joint testing driven by in situ mechanical characterization: From permeability of porous structures to dynamic wear monitoring.

Progress in biophysics and molecular biology·2026
Same journal

Proteostasis-driven redox adaptation in ferroptosis: the p62-Keap1-Nrf2 axis.

Progress in biophysics and molecular biology·2026
See all related articles

Related Experiment Video

Updated: Mar 16, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K

Myeloma bone disease: Progress in pathogenesis.

Hao Xi1, Ran An1, Lu Li1

  • 1Department of Hematology, The Myeloma and Lymphoma Center, Changzheng Hospital, Second Military Medical University, Shanghai, China.

Progress in Biophysics and Molecular Biology
|August 7, 2016
PubMed
Summary
This summary is machine-generated.

Myeloma bone disease (MBD), a severe complication of multiple myeloma (MM), involves dysregulated bone cells. Understanding the factors and signaling pathways driving MBD is crucial for developing new treatments.

Keywords:
Myeloma bone diseaseOsteoblastOsteoblast cell inactivating factorOsteoclastOsteoclast cell activating factor

More Related Videos

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Related Experiment Videos

Last Updated: Mar 16, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

7.3K
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.6K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K

Area of Science:

  • Oncology
  • Bone Biology
  • Cell Signaling

Background:

  • Myeloma bone disease (MBD) is a major complication of multiple myeloma (MM), causing significant morbidity.
  • The pathogenesis of MBD involves the dysregulation of osteoblast and osteoclast cells within the bone marrow microenvironment.
  • Myeloma cells and other bone marrow cells secrete cytokines that activate osteoclasts and inactivate osteoblasts, contributing to bone destruction.

Purpose of the Study:

  • To review recent advancements in understanding the factors involved in MBD pathogenesis.
  • To summarize the key signaling pathways implicated in the development and progression of MBD.
  • To identify potential therapeutic targets for managing MBD.

Main Methods:

  • Literature review of recent studies on MBD.
  • Analysis of cytokines and signaling pathways involved in bone metabolism in MM.
  • Synthesis of information on factors contributing to MBD pathogenesis.

Main Results:

  • Identification of specific osteoclast-activating factors (OAFs) and osteoblast-inactivating factors secreted in the MBD microenvironment.
  • Elucidation of critical signaling pathways that mediate the effects of these factors on bone cells.
  • Highlighting the complex interplay between myeloma cells and the bone microenvironment in driving MBD.

Conclusions:

  • A comprehensive understanding of MBD pathogenesis requires studying the secreted factors and signaling pathways.
  • Targeting these specific factors and pathways holds promise for future MBD therapies.
  • Further research into the molecular mechanisms of MBD is essential for improving patient outcomes.